
MDxHealth SA (MDXH) Stock Forecast & Price Target
MDxHealth SA (MDXH) Analyst Ratings
Bulls say
MDxHealth is a multinational healthcare company that specializes in personalized cancer diagnostics through their proprietary genomic and epigenetic technologies. Despite some setbacks with discontinued tests and lowered revenue estimates, the company's strategic acquisitions and expansion into high-growth areas show promise for future growth. Additionally, their strong performance in 2025 and continued confidence from management suggest that the company's fundamentals are solid, making it an attractive stock for investors.
Bears say
MDxHealth is heavily reliant on its urology-focused product portfolio and faces potential risks with the discontinuation of its UTI and Resolve tests, as well as potential reimbursement challenges for its GPS test. Additionally, the company's revenue growth and profit margins may be impacted by the integration of their recent ExoDx acquisition and the timing of contingent payments to Exact Sciences for the technology. These factors, combined with a potential double-digit revenue growth opportunity, create uncertainty for the company's financial performance, leading to a negative outlook.
This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.
MDxHealth SA (MDXH) Analyst Forecast & Price Prediction
Start investing in MDxHealth SA (MDXH)
Order type
Buy in
Order amount
Est. shares
0 shares